Compare Harmony Gold Mining Co. (HMY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Regeneron Pharmaceuticals Inc — how do they compare? Harmony Gold Mining Co. trades at $16.87 (market cap $10.02B), while Regeneron Pharmaceuticals Inc trades at $750.8 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.6× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays the higher dividend (4.63%). Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| HMY | REGN | |
|---|---|---|
Market Cap | $10.02B | $76.14B |
Volume | 3,643,683 | 500,239 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $852.03 |
52-Week Low | $13.32 | $557.73 |
Typical Hold Time | 45 Days | 107 Days |
Enterprise Value | $10.07B | $70.85B |
Dividend Yield | 4.63% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HMY trades at $16.83, up 2.03% today, amid a bearish technical signal from moving averages. The company reported record fiscal 2026 revenue of $99.2B and net income of $29.3B, with a strong net margin of 29.57%. Recent news highlights its strategic shift toward copper production, with the CEO noting the real payoff is expected after 2030. Cash flow from operations surged to $22.65B in 2025, though 2026 projections show a net cash outflow due to heavy investing.
The outlook is mixed: strong fundamentals and undervalued ratios (P/E of 6.02) support upside, but technical weakness and two recent EPS misses pose near-term risks. Analyst consensus is cautious with 70% hold ratings. Key opportunities include copper diversification; risks involve execution on investments and gold price volatility.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
